



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68		A1	(11) International Publication Number: WO 97/39148 (43) International Publication Date: 23 October 1997 (23.10.97)		
(21) International Application Number: PCT/US97/06064 (22) International Filing Date: 11 April 1997 (11.04.97)		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).			
(30) Priority Data: 08/630,672 12 April 1996 (12.04.96) US 08/689,873 15 August 1996 (15.08.96) US					
(71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Boulevard, Los Angeles, CA 90048-1965 (US).					
(72) Inventors: TARGAN, Stephen, R.; 428 Homewood Avenue, Los Angeles, CA 90049 (US). VASILIAUSKAS, Eric, A.; 221 33rd Street #A, Hermosa Beach, CA 90254 (US). PLEVY, Scott, E.; 1572 Palisades Drive, Pacific Palisades, CA 90272 (US). YANG, Huiying; 16409 Holmes Place, Cerritos, CA 90703 (US). ROTTER, Jerome, I.; 2617 Greenfield Avenue, Los Angeles, CA 90064 (US).					
(74) Agents: FUJITA, Sharon, M. et al.; Pretty Schroeder & Poplawski, Suite 2000, 444 South Flower Street, Los Angeles, CA 90071 (US).					
(54) Title: METHODS OF DIAGNOSING A CLINICAL SUBTYPE OF CROHN'S DISEASE WITH FEATURES OF ULCERATIVE COLITIS					
(57) Abstract					
<p>The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates the pANCA-positive subtype of CD.</p>					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

**METHODS OF DIAGNOSING A CLINICAL SUBTYPE OF CROHN'S DISEASE
WITH FEATURES OF ULCERATIVE COLITIS**

This work was supported by USPHS grant DK46763 awarded by The United States Public Health Service. The United 5 States government has certain rights in this invention.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The invention relates generally to the fields of autoimmunity and inflammatory bowel disease and more 10 specifically to serological and genetic methods for diagnosing a clinical subtype of Crohn's disease.

BACKGROUND INFORMATION

Inflammatory bowel disease (IBD) is the collective term used to describe two gastrointestinal disorders of unknown 15 etiology: Crohn's disease (CD) and ulcerative colitis (UC). The course and prognosis of IBD, which occurs world-wide and is reported to afflict as many as two million people, varies widely. Onset of IBD is predominantly in young adulthood with diarrhea, abdominal pain, and fever the three most common 20 presenting symptoms. The diarrhea may range from mild to severe and in ulcerative colitis often is accompanied by bleeding. Anemia and weight loss are additional common signs of IBD. Ten percent to fifteen percent of all patients with IBD will require surgery over a ten year period. In addition, 25 patients with IBD are at increased risk for the development of intestinal cancer. Reports of an increasing occurrence of psychological problems, including anxiety and depression, are perhaps not surprising symptoms of what is often a debilitating disease that strikes people in the prime of life.

30 Progress has been made in diagnosing IBD and in distinguishing, in many cases, Crohn's disease from ulcerative colitis. However, CD and UC each can represent a number of distinct disease subtypes that affect the gastrointestinal tract and produce similar symptoms. The heterogeneity 35 underlying CD, for example, can be reflected in the variable responses of CD patients to a particular treatment strategy. The availability of methods of diagnosing a clinical subtype

for the design of treatment modalities that are specific to a particular disease subtype. Unfortunately, a method of stratifying CD into clinical subtypes to allow the design of more precise treatment strategies is currently not available.

5 Thus, there is a need for a method of diagnosing a clinical subtype of CD. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides a method of diagnosing a 10 clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibody (pANCA) is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). Such a clinical subtype can be diagnosed, for 15 example, by obtaining a serum sample from a patient with CD; determining whether anti-neutrophil cytoplasmic antibody (ANCA) is detectable in patient sera diluted at least about 100-fold; and assaying for the presence or absence of a pANCA staining pattern, where detection of ANCA in patient sera 20 diluted at least about 100-fold and the presence of a pANCA staining pattern indicate the presence of pANCA, provided that detection of ANCA is not by histological methods.

The invention further provides a method of diagnosing a clinical subtype of CD by detecting an Arg²⁴¹ allele at an 25 ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates a clinical subtype of CD with features of ulcerative colitis. According to the methods of the invention, an Arg²⁴¹ allele can be detected by obtaining material from the patient with CD; preparing a nucleic acid comprising nucleotide 721 of 30 SEQ ID NO: 1 from the material; contacting the nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under conditions suitable for formation of a specific hybrid between the nucleic acid and the Arg²⁴¹ allele-specific oligonucleotide probe; and assaying for the presence of the specific hybrid, 35 where the presence of the specific hybrid indicates the Arg²⁴¹ allele.

In addition, the invention provides a method of

diagnosing a pANCA-positive subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates the pANCA-positive subtype of CD. A pANCA-positive subtype of CD can be diagnosed according to 5 the methods of the invention by obtaining material from a patient with CD; preparing a nucleic acid comprising nucleotide 721 of SEQ ID NO: 1 from the material; contacting the nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under conditions suitable for formation of a specific 10 hybrid between the nucleic acid and the Arg²⁴¹ allele-specific oligonucleotide probe; and assaying for the presence of the specific hybrid, where the presence of the specific hybrid indicates the Arg²⁴¹ allele.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 shows the inflammatory disease-associated ANCA in sera from Crohn's disease patients analyzed by indirect immunofluorescence and by ELISA, with results expressed as percent of positive control. The solid line in each column represents the mean binding, respectively.

20 Figure 2 shows the clinical symptoms of a Crohn's disease study population of 69 patients. The differences between groups without *p*-values are not statistically significant.

Figure 3 shows the anatomic distribution of disease by ANCA-negative, cANCA-positive and pANCA-positive CD subgroups. 25 Colonic involvement, with or without small bowel disease, was present in the majority of CD patients within each subgroup.

Figure 4 shows the nucleic acid sequence (SEQ ID NO: 1) and corresponding amino acid sequence of human intracellular adhesion molecule-1 (ICAM-1).

DETAILED DESCRIPTION OF THE INVENTION

Although Crohn's disease (CD) and ulcerative colitis (UC) generally have been considered distinct diseases, the present invention is directed to the surprising discovery that there is a clinical subtype of CD patients that also have features 35 of UC. The invention provides convenient, non-invasive serological and genetic assays for diagnosing this clinical subtype.

The invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether pANCA is present in a patient with CD, where the presence of pANCA indicates a clinical subtype of CD with features of ulcerative colitis (UC). A method of the invention for diagnosing a clinical subtype of CD by determining whether pANCA is present in a patient with CD can be practiced by obtaining a serum sample from the patient with CD; determining whether anti-neutrophil cytoplasmic antibody (ANCA) is detectable in patient sera diluted at least about 100-fold; and assaying for the presence or absence of a pANCA staining pattern, where detection of ANCA in patient sera diluted at least about 100-fold and the presence of a pANCA staining pattern indicate the presence of pANCA, if the detection of ANCA is not by histological means.

As disclosed herein, the presence of pANCA in a Crohn's disease patient indicates a clinical subtype of CD, which is characterized by features of ulcerative colitis in addition to the features that are typical of CD. As described in Example IA, the presence of pANCA was determined in a group of 69 CD patients, where pANCA was determined to be present if ANCA was detectable in patient sera diluted 100-fold using a fixed neutrophil enzyme-linked immunosorbent assay (ELISA) and if a pANCA staining pattern was present as determined by indirect immunofluorescence using fixed neutrophil. Using these criteria to establish whether pANCA was present in a patient with CD, 100% percent of CD patients in which pANCA was present exhibited features of ulcerative colitis (see Example IB). The frequency of features of ulcerative colitis in the pANCA-positive CD subgroup was significantly higher than the frequency of features of ulcerative colitis in the cANCA-positive subgroup (45%) or the ANCA-negative CD subgroup (39%). Although Crohn's disease and ulcerative colitis generally have been considered to be distinct disorders, these results demonstrate that a subtype of patients have inflammatory bowel disease characterized by features of both UC and CD. The present invention provides a non-invasive

assay based on the presence of pANCA to diagnose this clinical subtype of CD with features of ulcerative colitis.

The methods of the invention for diagnosing a clinical subtype of CD with features of ulcerative colitis are useful 5 for the medical management of this subtype of Crohn's patients. The heterogeneity underlying Crohn's disease generally is reflected in variable responses of CD patients to a given treatment strategy. However, pANCA-positive CD patients suffer from a similar type of mucosal inflammation 10 and respond similarly to a particular course of therapy. Furthermore, therapeutic strategies that are efficacious in the management of UC also can be used to treat the clinical subtype of CD with features of UC, while other Crohn's disease patients are unresponsive. For example, colectomy to remove 15 diseased colonic mucosa with creation of an ileal pouch to preserve continence is frequently recommended for uncontrolled UC. While the general population of Crohn's disease patients typically cannot tolerate a pouch, such surgery can be a viable option for the subtype of CD patients whose disease is 20 characterized by features of UC. Other therapeutic strategies, such as anti-tumor necrosis factor- α (TNF- α) inflammataries, for example, can best be used to treat Crohn's disease patients that are not pANCA-positive. Thus, the methods of the invention are useful for the differential 25 diagnosis, treatment and medical management of patients having CD.

Inflammatory bowel disease has been classified into the broad categories of Crohn's disease and ulcerative colitis. Crohn's disease (regional enteritis) is a disease of chronic 30 inflammation that can involve any part of the gastrointestinal tract. Commonly the distal portion of the small intestine (ileum) and cecum are affected. In other cases, the disease is confined to the small intestine, colon or anorectal region. Crohn's disease occasionally involves the duodenum and 35 stomach, and more rarely the esophagus and oral cavity.

The variable clinical manifestations of Crohn's disease are, in part, a result of the varying anatomic localization of

the disease. The most frequent symptoms of CD are abdominal pain, diarrhea and recurrent fever. CD is commonly associated with intestinal obstruction or fistula, which is an abnormal passage between diseased loops of bowel, for example. Crohn's 5 disease also includes complications such as inflammation of the eye, joints and skin; liver disease; kidney stones or amyloidosis. In addition, CD is associated with an increased risk of intestinal cancer.

Several features are characteristic of the pathology of 10 Crohn's disease. The inflammation associated with CD, known as transmural inflammation, involves all layers of the bowel wall. Thickening and edema, for example, typically also appear throughout the bowel wall, with fibrosis also present in long-standing disease. The inflammation characteristic of 15 CD also is discontinuous in that segments of inflamed tissue, known as "skip lesions," are separated by apparently normal intestine. Furthermore, linear ulcerations, edema, and inflammation of the intervening tissue lead to a "cobblestone" appearance of the intestinal mucosa, which is distinctive of 20 CD.

A hallmark of Crohn's disease is the presence of discrete aggregations of inflammatory cells, known as granulomas, which are generally found in the submucosa. About half of Crohn's disease cases display the typical discrete granulomas, while 25 others show a diffuse granulomatous reaction or nonspecific transmural inflammation. As a result, the presence of discrete granulomas is indicative of CD, although the absence of granulomas also is consistent with the disease. Thus, transmural or discontinuous inflammation, rather than the 30 presence of granulomas, is a preferred diagnostic indicator of Crohn's disease (Rubin and Farber, Pathology (Second Edition) Philadelphia: J.B. Lippincott Company (1994), which is incorporated herein by reference).

Ulcerative colitis (UC) is a disease of the large 35 intestine characterized by chronic diarrhea with cramping abdominal pain, rectal bleeding, and loose discharges of blood, pus and mucus. The manifestations of ulcerative

colitis vary widely. A pattern of exacerbations and remissions typifies the clinical course of most UC patients (70%), although continuous symptoms without remission are present in some patients with UC. Local and systemic complications of UC include arthritis, eye inflammation such as uveitis, skin ulcers and liver disease. In addition, ulcerative colitis and especially long-standing, extensive disease is associated with an increased risk of colon carcinoma.

Several pathologic features characterize UC in distinction to other inflammatory bowel diseases. Ulcerative colitis is a diffuse disease that usually extends from the most distal part of the rectum for a variable distance proximally. The term left-sided colitis describes an inflammation that involves the distal portion of the colon, extending as far as the splenic flexure. Sparing of the rectum or involvement of the right side (proximal portion) of the colon alone is unusual in ulcerative colitis. The inflammatory process of ulcerative colitis is limited to the colon and does not involve, for example, the small intestine, stomach or esophagus. In addition, ulcerative colitis is distinguished by a superficial inflammation of the mucosa that generally spares the deeper layers of the bowel wall. Crypt abscesses, in which degenerated intestinal crypts are filled with neutrophils, also are typical of ulcerative colitis (Rubin and Farber, *supra*, 1994).

In comparison with Crohn's disease, which is a patchy disease with frequent sparing of the rectum, ulcerative colitis is characterized by a continuous inflammation of the colon that usually is more severe distally than proximally. The inflammation in ulcerative colitis is superficial in that it is usually limited to the mucosal layer and is characterized by an acute inflammatory infiltrate with neutrophils and crypt abscesses. In contrast, Crohn's disease affects the entire thickness of the bowel wall with granulomas often, although not always, present. Disease that terminates at the ileocecal valve, or in the colon distal to it, is

indicative of ulcerative colitis, while involvement of the terminal ileum, a cobblestone-like appearance, discrete ulcers or fistulas suggest Crohn's disease. Characteristics that serve to distinguish Crohn's disease from ulcerative colitis 5 are summarized in Table 1 (Rubin and Farber, *supra*, 1994).

As used herein, the term "patient with Crohn's disease" is synonymous with "patient with CD" and means a patient having a characteristic feature from at least two of the following categories: clinical, endoscopic, radiographic and 10 histopathologic. As used herein, a characteristic clinical feature is perforating or fistulizing disease; or an obstructive symptom secondary to small bowel stenosis or stricture. As used herein, a characteristic endoscopic feature is a deep linear or serpiginous ulceration; a discrete 15 ulcer in normal-appearing mucosa; cobblestoning; or discontinuous or asymmetric inflammation. As used herein, a characteristic radiographic feature is segmental disease (skip lesion); a small bowel or colon stricture; stenosis or fistula. As used herein, a characteristic histopathologic 20 feature is submucosal or transmural inflammation; multiple granulomas; marked focal cryptitis or focal chronic inflammatory infiltration within and between biopsies; or a skip lesion, including histologic rectal sparing in the absence of local therapy.

Table 1

Feature	Crohn's Disease	Ulcerative Colitis
Macroscopic		
Thickened bowel wall	Typical	Uncommon
Luminal narrowing	Typical	Uncommon
"Skip" lesions	Common	Absent
Right colon predominance	Typical	Absent
Fissures and fistulas	Common	Absent
Circumscribed ulcers	Common	Absent
Confluent linear ulcers	Common	Absent
Pseudopolyps	Absent	Common
Microscopic		
Transmural inflammation	Typical	Uncommon
Submucosal fibrosis	Typical	Absent
Fissures	Typical	Rare
Granulomas	Common	Absent
Crypt abscesses	Uncommon	Typical

As used herein, the term "features of ulcerative colitis" or "features of UC" means clinical features of left-sided colonic disease accompanied by a characteristic endoscopic or histopathologic feature of UC. Clinical features of left-sided colonic disease, as used herein, are rectal bleeding, urgency and tenesmus. The rectal bleeding can be accompanied by mucus discharge. An additional typical clinical feature can be treatment with topical therapy or recommended or performed total or near-total colectomy. A characteristic endoscopic feature of UC, which when present with clinical features of left-sided colonic disease indicates features of ulcerative colitis, is inflammation that is more severe distally than proximally or continuous inflammation. An additional typical endoscopic feature can be inflammation extending proximally from the rectum or shallow ulcerations or

the lack of deep ulcerations. A characteristic histopathologic feature of UC, which when present with clinical features of left-sided colonic disease indicates features of ulcerative colitis, is homogeneous, continuous, 5 predominantly superficial inflammation or a lack of "focality" within biopsy specimens. An additional typical histopathologic feature can be a crypt abscess or the lack of granulomas. Characteristic clinical, endoscopic and histopathologic features of ulcerative colitis are summarized 10 in Table 2.

Patients with chronic inflammatory bowel disease generally are characterized as having either Crohn's disease or ulcerative colitis to describe specific patterns of disease, to predict outcomes based on expected natural 15 histories, and to help guide medical and surgical treatment strategies. Clinical, endoscopic, and histopathologic criteria, as discussed above, have been developed to classify patients into one or the other category. However, overlap between CD and UC also has been demonstrated at a variety of 20 levels by clinical, immunological and genetic studies, for example. Furthermore, CD and UC each can encompass a number of distinct conditions affecting the gastrointestinal tract, with different clinical subtypes being classified together as CD or UC because they present with similar symptoms. The 25 present invention is directed to the discovery that such a clinical subtype, in particular a clinical subtype of CD with features of ulcerative colitis, can be diagnosed using perinuclear anti-neutrophil cytoplasmic antibodies (pANCA).

In one embodiment, present invention provides a method of 30 diagnosing a clinical subtype of CD by determining whether pANCA is present in a patient with CD, by obtaining a serum sample from the patient with CD; determining whether ANCA is detectable in patient sera diluted at least about 100-fold and assaying for the presence or absence of a pANCA staining 35 pattern, where detection of ANCA in patient sera diluted at least about 100-fold and the presence of a pANCA staining pattern indicate the presence of pANCA, provided that

detection of ANCA is not by histological means.

Anti-neutrophil cytoplasmic antibodies that produce a perinuclear staining pattern are elevated in 68-80% of UC patients and less frequently in CD and other disorders of the 5 colon. Serum titers of ANCA are elevated regardless of clinical status and, thus, do not reflect disease activity. High levels of serum ANCA also persist in patients five years post-colectomy. Although pANCA is found only very rarely in healthy adults and children, healthy relatives of UC patients 10 have an increased frequency of pANCA, indicating that pANCA may be an immunogenetic susceptibility marker.

Serum antibodies to cytoplasmic components of a neutrophil can be detected, for example, using indirect immunofluorescence microscopy of alcohol-fixed neutrophils. 15 ANCA activity has been divided into two broad categories: cytoplasmic neutrophil staining (cANCA) and a perinuclear to nuclear staining or cytoplasmic staining with perinuclear highlighting (pANCA). The term "anti-neutrophil cytoplasmic antibody" is synonymous with "ANCA" and encompasses both pANCA 20 and cANCA. As used herein, the term "perinuclear anti-neutrophil cytoplasmic antibody" is synonymous with "pANCA" and refers to an antibody that reacts specifically with a neutrophil to give perinuclear to nuclear staining or cytoplasmic staining with perinuclear highlighting. The term 25 pANCA-positive, when used in reference to a patient, means a patient having pANCA. The term "pANCA staining pattern" means a perinuclear to nuclear staining pattern or a cytoplasmic staining pattern with perinuclear highlighting that distinguishes pANCA from, for example, cANCA.

Table 2

A. Clinical features of left-sided colonic disease	1. Rectal bleeding possibly accompanied by mucus discharge 2. Urgency 3. Tenesmus 4. Treatment with topical therapy 5. Recommended or performed total or near-total colectomy
B. Endoscopic features of UC	6. Inflammation that is more severe distally than proximally 7. Continuous inflammation 8. Inflammation extending proximally from the rectum 9. Shallow ulcerations or lack of deep ulcerations
C. Histopathologic features of UC	10. Homogeneous, continuous, predominantly superficial inflammation 11. Lack of "focality" within biopsy specimens 12. Crypt abscesses 13. Lack of granulomas

10 Previous studies have consistently shown ANCA reactivity in a small portion of patients with Crohn's disease. The reported prevalence varies from 0 to 43% with most studies reporting that between 10-30% of CD patients express ANCA (see, for example, Saxon et al., *supra*, 1990; Cambridge et al., *Gut* 33:668-674 (1992); Pool et al., *Gut* 34:46-50 (1993); and Brokroelofs et al., *Dig. Dis. Sci.* 39:545-549 (1994)).

15 The pANCA-positive subtype of Crohn's disease does not correlate with traditional CD subgroups based on, for example, location of disease (small bowel only, colon only, or small bowel and colon); extent of disease; duration of illness;

disease activity; medical therapy; or surgical history (Cambridge et al., *supra*, 1992; Pool et al., *supra*, 1993; Brokroelofs et al., *supra*, 1994). Previous work has suggested that ANCA expression in CD patients may be related 5 to colonic disease (Sung et al., *Dig. Dis. Sci.* 39:886-892 (1994); Proujansky et al., *J. Pediatr. Gastroenterol. Nutr.* 17:193-197 (1993); and Patel et al., *Br. J. Surg.* 81:724-726 (1994)). However, as disclosed herein, the majority of CD 10 patients with colonic disease are not pANCA-positive, and the presence of colonic disease alone does not characterize the pANCA-positive subtype of CD patients (see Example IB). As disclosed herein, the presence of pANCA in CD is instead diagnostic of features of ulcerative colitis such as left-sided colonic disease in which the distal portion of the 15 colon is more severely inflamed than the proximal portion and clinical symptoms of left-sided colonic inflammation such as rectal bleeding (see Figure 2).

In a previous study, biopsy specimens from two Crohn's disease patients, which had a PANCA staining pattern as 20 determined by indirect immunofluorescence, contained features of both UC and CD (Hardarson et al., *Am. J. Clin. Pathol.* 99:277-281 (1993)). Therefore, previous work has suggested in a very small sample that a PANCA staining pattern in a CD patient is consistent with endoscopic features of ulcerative 25 colitis. However, the present invention is directed to determining whether pANCA is present by detection of ANCA in patient sera diluted at least 100-fold in combination with the presence of a pANCA staining pattern, provided that detection of ANCA is not by histological means. In contrast, Hardarson 30 et al. performed immunofluorescence to assay for a pANCA staining pattern and to titer patient sera. The use of histological means, including cell staining methods such as indirect immunofluorescence, for determining whether ANCA is detectable in patient sera diluted at least about 100-fold are 35 explicitly excluded from the present invention. In addition, the present invention is directed to the discovery that the presence of pANCA indicates a clinical subtype of CD with

features of UC, where these features include clinical features as well as endoscopic or histopathologic features. Clinical features of UC had not been associated with the presence of pANCA in a patient with CD prior to the present invention.

5 A clinical subtype of CD with features of ulcerative colitis indicates overlap between CD and UC previously has been demonstrated. Such a clinical subtype is consistent with the relatively frequent co-occurrence of CD and UC within the same family, which indicates that these two forms of IBD, or
10 a subtype of each disease, share a common genetic background. The familial co-occurrence of CD and UC has suggested that three genetically distinct forms of IBD exist: CD alone; UC alone and a third leading to both CD and UC (Toyoda et al., Gastroenterol. 104:741-748 (1993)).

15 A subtype of CD patients expressing ANCA previously has been shown to have an increased frequency of familial co-occurrence of CD and UC (Yang et al., Gastroenterol. 109:440-448 (1995)). However, in this analysis, serum ANCA was measured without determining if the ANCA was associated
20 with a pANCA staining pattern. Furthermore, in contrast to the present invention, Yang et al., *supra*, 1995, demonstrated that a subgroup of ANCA-positive CD patients have family members with ulcerative colitis, but do not provide a method of diagnosing a clinical subtype where features of both UC and
25 CD are present within the same patient.

Methods useful in determining the presence of pANCA in a patient with CD are described herein (see Example IA) and are known in the art. The presence of pANCA can be determined using a sample obtained from any biological fluid such as, for
30 example, whole blood, plasma or other bodily fluid or tissue having pANCA, preferably serum. When multiple samples are used in an assay for determining the presence of pANCA, it is preferred that the same type of biological fluid or tissue is used for each sample. As used herein, the term "patient" means
35 any animal capable of producing pANCA including, for example, a human, non-human primate, rabbit, rat or mouse. A sample to be assayed for the presence of pANCA can be obtained from any

such patient.

A serum sample diluted at least about 100-fold is particularly useful in the methods of the invention. As disclosed herein, the presence of pANCA in a patient with CD 5 is preferably determined by obtaining a serum sample from the patient with CD; determining whether ANCA is detectable in patient sera diluted at least about 100-fold and assaying for the presence or absence of a pANCA staining pattern, where detection of ANCA in patient sera diluted at least about 10 100-fold and the presence of a pANCA staining pattern indicate the presence of pANCA, provided that the detection of ANCA is not by histological means. Numerous studies have used indirect immunofluorescence alone to detect the presence of serum ANCA, thereby determining whether pANCA is present 15 simply on the basis of a pANCA staining pattern. Furthermore, where a quantitative assay has been relied upon in addition to a pANCA staining pattern, detection of ANCA has been determined using a relatively high concentration of patient sera, such as a 20-fold or 40-fold dilution of sera, for 20 example. In contrast, the present invention is directed to the novel discovery that the presence of pANCA, as determined rigorously by both detection of ANCA in patient sera diluted at least about 100-fold and the presence of a pANCA staining pattern, is diagnostic of a clinical subtype of CD with 25 features of ulcerative colitis, provided that detection of ANCA in patient sera is not by histological means.

As used herein, the term "histological means," when used in reference to detection of ANCA or detection of a first complex of antigen and ANCA, refers to a technique for 30 studying the structure of a cell or tissue using staining and microscopy. Histological means, which encompass techniques such as immunocytochemistry and indirect immunofluorescence, can distinguish cANCA and pANCA staining patterns and, thus, are useful in assaying for the presence or absence of a pANCA 35 staining pattern, for example. However, histological means, which typically are subjective, are not useful for rigorously determining whether ANCA is detectable in patient sera diluted

at least about 100-fold. The use of histology, as defined herein, for determining whether ANCA is detectable in patient sera diluted at least about 100-fold are explicitly excluded from the present invention. Similarly, the present invention 5 explicitly excludes the use of histological means to detect the presence or absence of a first complex of antigen and ANCA.

It is recognized that determining whether ANCA is detectable in patient sera diluted at least about 100-fold can 10 be performed prior to, following or concurrent with assaying for the presence or absence of a pANCA staining pattern. Thus, for example, an immunofluorescence assay for the presence of a pANCA staining pattern followed by an enzyme-linked immunosorbent assay for determining whether ANCA 15 is detectable in patient sera diluted at least about 100-fold is encompassed within the methods of the invention.

Methods of determining whether ANCA is detectable in patient sera diluted at least about 100-fold are well known in the art (Harlow and Lane, Antibodies: A Laboratory Manual New 20 York: Cold Spring Harbor Laboratory (1988), which is incorporated herein by reference). For example, ANCA can be detected in patient sera using a detectable reagent such as a secondary antibody labeled with a detectable enzymatic, radioisotopic, fluorescent or chemilumine scent marker. 25 Particularly useful methods include a quantitative assay such as an immunoassay, in which an antibody selective for ANCA is used to detect ANCA in patient sera. A radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA), for example, is encompassed within the invention. As discussed above, the 30 present invention explicitly excludes the use of histological means such as immunocytochemistry or immunofluorescence for determining whether ANCA is present in patient sera diluted at least about 100-fold.

An enzyme-linked immunosorbent assay (ELISA) can be 35 useful in determining whether ANCA is present in patient sera diluted at least about 100-fold. For example, a fixed neutrophil ELISA for detection of ANCA in patient sera diluted

100-fold is described in Example IA. An enzyme that is linked to a secondary antibody selective for ANCA can be, for example, horseradish peroxidase (HRP), alkaline phosphatase (AP), β -galactosidase or urease. A horseradish-peroxidase detection system can be used, for example, with the chromogenic substrate tetramethylbenzidine (TMB), which yields a soluble product in the presence of hydrogen peroxide that is detectable at 450 nm. An alkaline phosphatase detection system can be used with the chromogenic substrate *p*-nitrophenyl phosphate, for example, which yields a soluble product readily detectable at 405 nm. Similarly, a β -galactosidase detection system can be used with the chromogenic substrate *o*-nitrophenyl- β -D-galactopyranoside (ONPG), which yields a soluble product detectable at 410 nm, or a urease detection system can be used with a substrate such as urea-bromocresol purple (Sigma Immunochemicals, St. Louis, MO). A secondary antibody linked to an enzyme is a detectable reagent useful in an ELISA and can be obtained from a number of commercial sources. For example, goat F(ab')₂ anti-human IgG-alkaline phosphatase can be purchased from Jackson Immuno-Research (West Grove, PA).

A radioimmunoassay also can be useful in determining whether ANCA is present in patient sera diluted at least about 100-fold. A radioimmunoassay using, for example, an iodine-125 labeled secondary antibody (Harlow and Lane, *supra*, 1988) is encompassed within the invention.

A secondary antibody labeled with a chemiluminescent marker also can be useful for determining whether pANCA is present. Such a chemiluminescent secondary antibody is convenient for sensitive, non-radioactive detection of pANCA and can be obtained commercially from various sources such as Amersham Lifesciences, Inc. (Arlington Heights, IL).

In addition, a detectable reagent labeled with a fluorochrome can be useful in determining whether ANCA is present in patient sera diluted at least about 100-fold. Appropriate fluorochromes include, for example, DAPI, fluorescein, Hoechst 33258, R-phycocyanin, B-phycoerythrin,

R-phycoerythrin, rhodamine, Texas red or lissamine. A particularly useful fluorochrome is fluorescein or rhodamine. A secondary antibody linked to a fluorochrome is a particularly useful detectable reagent and can be obtained 5 commercially. For example, goat F(ab')₂ anti-human IgG-FITC is available from Tago Immunologicals (Burlingame, CA).

A signal from the detectable reagent can be analyzed, for example, using a spectrophotometer to detect color from a chromogenic substrate; a radiation counter to detect 10 radiation, such as a gamma counter for detection of iodine-125; or a fluorometer to detect fluorescence in the presence of light of a certain wavelength. For detection of enzyme-linked reagents, a quantitative analysis of the amount 15 of ANCA can be made using a spectrophotometer such as an EMAX Microplate Reader (Molecular Devices, Menlo Park, CA) in accordance with the manufacturer's instructions. If desired, the assays of the invention can be automated or performed robotically, and the signal from multiple samples can be detected simultaneously.

20 Immunoassays using a secondary antibody that binds ANCA selectively are particularly useful for determining whether ANCA is detectable in patient sera diluted at least about 100-fold. For example, an anti-Ig antibody such as anti-IgG is selective for ANCA and useful in the methods of the 25 invention when labeled with a detectable marker such as an enzyme, fluorochrome or radioactive isotope. A useful secondary antibody is selective for the species of the ANCA to be detected. For example, if human serum is the sample to be assayed, mouse anti-human IgG can be a useful detectable 30 reagent. In addition, a second selective binding reagent can be useful in detecting ANCA. For example, a goat anti-mouse antibody, which is selective for the class determining portion of the mouse anti-human IgG antibody, can be used in combination with mouse anti-human IgG to detect ANCA in human 35 sera.

A secondary antibody useful in an immunoassay of the invention can be obtained commercially or by techniques well

known in the art. Such an antibody can be a polyclonal or, preferably, monoclonal antibody that binds ANCA selectively. For example, IgG reactive polyclonal antibodies can be prepared using IgG or Fc fragments of IgG as an immunogen to 5 stimulate the production of antibodies in the antisera of an animal such as a rabbit, goat, sheep or rodent, for example (Harlow and Lane, *supra*, 1988).

A monoclonal antibody useful in the practice of the invention can be obtained from a number of commercially 10 available sources. In addition, an immunogen useful to generate a monoclonal antibody that binds ANCA selectively can be, for example, human IgG or a Fc fragment of human IgG, ANCA or a Fab fragment of ANCA. A hybridoma that produces a monoclonal selective for ANCA can be identified by screening 15 hybridoma supernatants for the presence of antibodies that bind ANCA specifically (Harlow, *supra*, 1988). For example, such a screening method can be a radioimmunoassay or enzyme-linked immunosorbent assay using neutrophil and pANCA-positive sera, for example.

20 Methods of assaying for the presence or absence of a pANCA staining pattern also are well known in the art. Methods of cell staining using, for example, neutrophil, are useful for determining the subcellular localization of ANCA reactivity, thereby differentiating pANCA from cANCA. 25 Immunocytochemistry or immunofluorescence are particularly useful for assaying for the presence of a pANCA staining pattern (Harlow and Lane, *supra*, 1988). An enzyme-labeled or fluorochrome labeled secondary antibody that binds ANCA selectively, such as described above, can be useful in such 30 methods. For example, indirect immunofluorescence readily can be performed by incubating methanol-fixed neutrophil with a 1:20 dilution of human sera and detecting the complex formed with fluorescein-labeled F(ab')₂ γ chain secondary antibody. The presence or absence of the pANCA staining pattern in the 35 stained cells is visualized using fluorescence microscopy as described in Saxon et al., *supra*, 1990, or in Example IA.

In one embodiment, the invention provides a method of

diagnosing a clinical subtype of CD by determining whether pANCA is present in a patient with CD by obtaining a serum sample from the patient with CD; contacting the serum sample diluted at least about 100-fold with antigen specific for ANCA under conditions suitable to form a first complex of antigen and ANCA; detecting the presence or absence of the first complex; contacting an appropriate dilution of the serum sample with antigen specific for ANCA under conditions suitable to form a second complex of neutrophil and ANCA; and assaying for the presence or absence of a pANCA staining pattern by detecting the presence or absence of the second complex, where the presence of the first complex and the presence of a pANCA staining pattern indicate the presence of pANCA, provided that detection of the first complex is not by histological means.

As used herein, the term "antigen specific for ANCA" is an antigen or mixture of antigens that is bound specifically by anti-neutrophil cytoplasmic antibody. For example, neutrophil is a particularly useful antigen specific for ANCA that can be obtained from a variety of sources, such as from blood derived from a human, non-human primate, rabbit, rat or mouse. Methods for preparing neutrophil are well known in the art; for example, human neutrophil can be prepared from human peripheral blood using sedimentation in 1% dextran as described in Saxon et al., *supra*, 1990. Preferably, neutrophil employed in the assay will have specific reactivity with the species from which the serum sample is obtained. For example, in an assay for ANCA or pANCA from a human patient, a human neutrophil is preferably employed. In addition, an antigen purified from neutrophil, which is bound specifically by ANCA, also can be an antigen specific for ANCA useful in the present invention.

The invention further provides a method of diagnosing a clinical subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates a clinical subtype of CD with features of ulcerative colitis. According to the methods of the invention, an Arg²⁴¹

allele can be detected by obtaining material from the patient with CD; preparing a nucleic acid comprising nucleotide 721 of SEQ ID NO: 1 from the material; contacting the nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under 5 conditions suitable for formation of a specific hybrid between the nucleic acid and the Arg²⁴¹ allele-specific oligonucleotide probe; and assaying for the presence of the specific hybrid, where the presence of the specific hybrid indicates the Arg²⁴¹ allele.

10 In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates the pANCA-positive subtype of CD. A pANCA-positive subtype of CD can be diagnosed according to 15 the methods of the invention by obtaining material from a patient with CD; preparing a nucleic acid comprising nucleotide 721 of SEQ ID NO: 1 from the material; contacting the nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under conditions suitable for formation of a specific 20 hybrid between the nucleic acid and the Arg²⁴¹ allele-specific oligonucleotide probe; and assaying for the presence of the specific hybrid, where the presence of the specific hybrid indicates the Arg²⁴¹ allele.

Inflammatory bowel disease is characterized by a failure 25 to down-regulate the usual self-limited gut inflammatory response, suggesting that one or more of the predisposing genes could be those that determine the level of the immune response along the inflammatory pathway. Evidence for a genetic component to Crohn's disease includes consistent 30 ethnic differences in disease frequency that cross different geographic areas; the familial occurrence of IBD; the existence of genetic syndromes that feature inflammatory bowel disease; and associations between IBD and genetic markers.

Host genetic factors involved in inflammatory bowel 35 disease can be molecules involved in immune recognition and specificity, such as HLA or T-cell receptor alleles or immunoglobulin allotypes, termed immunospecific genes. Host

genetic factors important in IBD also include inflammatory cell adhesion molecules, which are essential for interaction of circulating leukocytes with the endothelium during immune and inflammatory reactions and for B and T-cell activation.

5 Intracellular adhesion molecule-1 (ICAM-1), is a member of the immunoglobulin gene superfamily that plays an important role in inflammation. *In vitro* studies have shown that ICAM-1 is involved in transendothelial migration of neutrophils, mixed lymphocyte response, and T-cell activation. (Harlan et al., Adhesion, Its Role in Inflammatory Disease, New York: Freeman (1992); Springer et al., Leukocyte Adhesion Molecules Structure, Function, and Regulation, New York: Springer Verlag (1988); Damie et al., J. Immunol. 148:655-671 (1992)). *In vivo* studies have shown that an anti-ICAM-1 monoclonal antibody can inhibit migration of neutrophils in response to 10 inflammation of the lung, peritoneum or myocardium (Barton et al., J. Immunol. 143:1278-1282 (1989); Harlan et al., *supra* (1992)). In particular, increased expression of ICAM-1 in colon has been observed in UC and CD (Malizia et al., 15 Gastroenterol. 100:150-159 (1991)). Mice rendered deficient in ICAM-1 by gene targeting also have abnormal inflammatory responses, including impaired neutrophil emigration (Sligh et al., Proc. Natl. Acad. Sci USA 90:8529-8533 (1993)). Thus, induction of ICAM-1 on mononuclear phagocytes can be important 20 in maintenance of chronic inflammation by facilitating, for example, neutrophil emigration from the vasculature or by acting as a co-stimulatory molecule in the immune response.

ICAM-1 has five immunoglobulin-like domains; domains one and three are functionally important in that they bind 25 leukocyte integrin. A single base change, corresponding to an amino acid polymorphism, is located at codon 241 in exon 4 (immunoglobulin-like domain three). Arg²⁴¹ (AGG) or Gly²⁴¹ (GGG) can be present at this position (see, for example, Vora et al., Genomics 21:473-477 (1994), which is incorporated 30 herein by reference). The present invention is directed to the discovery that the frequency of the Arg²⁴¹ ICAM-1 allele is significantly higher in the pANCA-positive subtype of CD than 35

in cANCA-positive or ANCA-negative subtypes. Thus, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, where the Arg²⁴¹ allele indicates the 5 pANCA-positive subtype of CD.

As disclosed herein, Crohn's disease patients can be subtyped according to the presence of pANCA, where the presence of pANCA is defined by detection of ANCA in patient sera diluted at least about 100-fold and the presence of a 10 pANCA staining, provided that detection of pANCA is not by histological means. As described in Example II, stratification of CD patients according to pANCA status reveals a significant association of the Arg²⁴¹ allele with the pANCA-positive subtype of CD. The results summarized in Table 15 6 indicate that 50% of pANCA-positive CD have the ICAM-1 Arg²⁴¹ allele as compared to only about 15% of pANCA-negative CD patients. The presence of pANCA, as discussed above, can be used to diagnose a clinical subtype of CD with features of ulcerative colitis. Thus, the association of the ICAM-1 Arg²⁴¹ 20 allele with pANCA-positive CD also provides the basis for a method of diagnosing a clinical subtype of CD with features of ulcerative colitis by detecting an Arg²⁴¹ at an ICAM-1 locus.

As used herein, the term "material" means any biological matter from which a nucleic acid can be prepared. For 25 example, the term material encompasses whole blood, plasma or other bodily fluid or tissue that contains nucleic acid. A preferred material is patient sera, which can be obtained readily by non-invasive means and used to prepare a nucleic acid for the diagnosis of Crohn's disease according to the 30 methods of the invention.

As used herein, the term "nucleic acid" means a polynucleotide such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). A nucleic acid can be either single-stranded or double-stranded. To practice the methods 35 of the invention, a particularly useful nucleic acid is genomic DNA, complementary DNA or messenger RNA. The term nucleic acid molecule, as used herein, encompasses a nucleic

acid or oligonucleotide.

As used herein, the term "locus" means a physical location, place or position occupied by a particular gene on a chromosome. As used herein, the term "ICAM-1 locus" means 5 any nucleic acid or chromosomal segment that encodes ICAM-1 or that influences expression of any ICAM-1 gene.

As used herein, the term "allele" means an alternative gene sequence that occupies the same chromosomal locus, with an alternative gene sequence including any modification or 10 variation of a gene.

An allele at a polymorphic locus, such as the Arg²⁴¹ allele, can be detected by a variety of methods including assays using the polymerase chain reaction (PCR). Allele-specific oligonucleotide hybridization (see Mullis et 15 al. (ed.), The Polymerase Chain Reaction Boston: Birkhäuser (1994), which is incorporated herein by reference), denaturing gradient gel electrophoresis (see, for example, Innis et al., PCR Protocols: A Guide to Methods and Application, San Diego: Academic Press, Inc. (1990)) and restriction fragment length 20 polymorphism based methods (Sambrook et al., *supra*, 1989), for example, are well known in the art and encompassed within the invention.

As used herein, the term "Arg²⁴¹ allele-specific oligonucleotide probe" means a nucleic acid molecule that will 25 form a specific hybrid, under appropriate conditions, with a nucleic acid including nucleotide 721 of SEQ ID NO: 1, such that one allele is distinguished from another allele. Thus, for example, an Arg²⁴¹ allele-specific oligonucleotide probe will form a hybrid with a nucleic acid including an adenine at 30 nucleotide 721 of SEQ ID NO: 1, but will not form a hybrid with a nucleic acid including a guanine at nucleotide 721 of the sequence shown in Figure 4 (SEQ ID NO: 1). Appropriate conditions for formation of a specific hybrid such that, for example, a single nucleotide mis-match between a nucleic acid 35 and an allele-specific oligoprobe will preclude formation of a hybrid are well known in the art (Sambrook et al., *supra*, 1989) and are described in Example II.

An Arg²⁴¹ allele-specific oligonucleotide probe preferably is a nucleic acid having from about seven to about thirty-five nucleotides. More preferably, an Arg²⁴¹ allele-specific oligonucleotide probe has from about twelve to about 5 thirty-five nucleotides and most preferably has from about seventeen to about twenty-five nucleotides. An Arg²⁴¹ allele-specific oligonucleotide probe can be a nucleic acid comprising, for example, CTGCACG (SEQ ID NO: 2); TGCACGG (SEQ ID NO: 3); GCACGGG (SEQ ID NO: 4); CACGGGC (SEQ ID NO: 5); 10 ACGGGCT (SEQ ID NO: 6); CGGGCTG (SEQ ID NO: 7); and GGGCTGT (SEQ ID NO: 8), or a complementary sequence thereto. A particularly useful Arg²⁴¹ allele-specific oligonucleotide probe is 5'TCCCTGGACAGGCTGTTCC3' (SEQ ID NO: 9).

As used herein, the term "under conditions suitable for 15 formation of a specific hybrid" means any set of parameters, physical conditions (such as temperature) or chemical conditions (such as pH, salt concentration) such that an oligonucleotide probe will form a hydrogen bonded, sequence-specific association with the nucleic acid target sequence to 20 which the oligonucleotide probe is complementary. Defining such parameters and conditions is routine to one skilled in the art, and for example is described in Sambrook et al., *supra*, 1989, and Mullis et al., *supra*, 1994, both of which have been incorporated herein by reference.

25 The following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

Comparison of the clinical feature of pANCA-positive and pANCA-negative CD patients

This example demonstrates that the pANCA status of
5 Crohn's disease patients correlates with a clinical subtype of
Crohn's disease having features of ulcerative colitis.

A. Determination of patient ANCA status by ELISA and indirect immunofluorescence assay

Presence of ANCA was determined by fixed neutrophil ELISA

10 A fixed neutrophil enzyme-linked immunosorbent assay was used to detect ANCA as described in Saxon et al., *supra*, 1990, which is incorporated herein by reference, and all samples were analyzed in a blinded fashion. Microliter plates were coated with 2.5×10^5 neutrophils per well and treated with
15 100% methanol to fix the cells. Cells were incubated with 0.25% bovine serum albumin (BSA) in phosphate-buffered saline to block nonspecific antibody binding. Next, control and coded sera were added at a 1:100 dilution to the bovine serum/phosphate-buffered saline blocking buffer. Alkaline
20 phosphatase conjugated goat F(ab')₂ anti-human immunoglobulin G (γ -chain specific) antibody (Jackson Immunoresearch Labs, Inc., West Grove, PA) was added at a 1:1000 dilution to label neutrophil bound antibody. A *p*-nitrophenol phosphate substrate solution was added and color development was allowed
25 to proceed until absorbance at 405 nm in the positive control wells was 0.8-1.0 optical density units greater than the absorbance in blank wells. The results were expressed as percent of standard binding with pANCA-positive defined as greater than two standard deviations (SD) above mean of
30 control. Titers were also determined.

Indirect immunofluorescence assay for determination of ANCA staining pattern

Indirect immunofluorescent staining was performed on

samples that were ANCA-positive by ELISA to determine whether the predominant staining pattern was perinuclear (pANCA) or cytoplasmic (cANCA). Glass slides containing approximately 100,000 neutrophils per slide were prepared by 5 cytocentrifugation (Shandon Cytospin, Cheshire, England) and they were fixed in 100% methanol, air-dried, and stored at -20°C. The fixed neutrophils were incubated with human sera were diluted (1:20), and the reaction was visualized with fluorescein-labeled F(ab')₂ γ chain-specific antibody as 10 described in Saxon et al., *supra*, 1990. The slides were examined using an epifluorescence-equipped Olympus BH-2 microscope (Olympus, Lake Success, NY).

Characteristics of Anti-Neutrophil Cytoplasmic Antibodies from CD patients

15 Serum ANCA was detected in 38/69 (55%) of the CD study population. ANCA-positive CD patients demonstrated a slight predominance of cytoplasmic staining (53%) as compared to periplasmic staining (47%), although this did not reach statistical significance ($p_c=0.75$). The mean ELISA binding 20 level of the pANCA-positive CD serum samples (41 ± 6) was higher than those that were cANCA-positive (16 ± 1 ; $p<0.000001$) or ANCA-negative (6 ± 1 ; $p<0.000001$) (see Figure 1). Provided at the right of Figure 1 for comparison are mean binding levels 25 of historical ANCA-positive controls as described by Duerr et al., *Gastroenterol.* 100:1590-1596 (1991), which is incorporated herein by reference. The pANCA-positive and cANCA-positive subgroups are denoted "p" and "c," Comparison of the mean ELISA binding levels of the pANCA-positive, cANCA-positive, and ANCA-negative CD subgroups to historical 30 means for ANCA+ UC patients from data by Duerr et al., *supra*, 1991 (pANCA-positive UC: 65 ± 6 ; cANCA+ UC: 36 ± 2), indicated that ANCA is present at lower levels in ANCA+ CD patients than ANCA+ UC patients. The mean titer of the pANCA-positive CD subgroup (512 ± 87) was higher than that of the cANCA+ subgroup 35 (227 ± 25) ($p=0.0024$).

Statistical analysis

Statistical analysis was performed using Student's t tests for comparisons of quantitative variables between two groups. Yate's continuity corrected χ^2 tests, denoted by p_c , 5 were used for comparisons of qualitative variables between two or more groups. When the expected number of a cell is less than 5, Fisher's exact tests were also calculated for comparisons between two proportions and corresponding p-values were denoted by $p_{Fisher's\ exact}$. Log transformations were performed 10 for ANCA titers to obtain a normal distribution for hypothesis testing.

B. Clinical symptoms of pANCA-positive and pANCA-negative CD patients**Clinical assessment and characterization of Crohn's disease 15 patients**

Clinical information for 69 CD patients was collected by chart review and patient interview by clinical investigators who were blind to individual patient ANCA status. Epidemiological data included: age, age at onset of IBD 20 symptoms, disease duration, gender, ethnicity, and family history of IBD. For each patient, all areas of endoscopically, surgically, histopathologically, or radiographically documented inflammation, stricturing, fistulization, or perforation were recorded. For purpose of 25 analysis, anatomic location of disease was further grouped into categories of "small bowel disease only," "ileocolonic disease," and "colonic involvement only." Signs and symptoms associated with active Crohn's disease were noted, including: obstructive symptoms, diarrhea, bleeding and mucus discharge, 30 urgency, tenesmus, perianal abscess or fistula, anal fissures or strictures, as well as extraintestinal manifestations of IBD. Pharmacological interventions were grouped to reflect the use of sulfasalazine or oral 5-ASA products; immunomodulatory agents such as 6-mercaptopurine/azathioprine,

methotrexate, cyclosporin or anti-TNF antibody therapy; IBD-directed antibiotic therapy; or topical therapy for distal colonic disease such as enemas, foams or suppositories. Steroid use was noted and further quantified into estimated 5 total years of systemic corticosteroid exposure, termed "steroid years." The number, type, and reason for all IBD-related surgeries also was recorded.

CD patients were examined for "features of ulcerative colitis." Features of ulcerative colitis were defined as 10 clinical features of left-sided colonic disease, including a combination of the typical left-sided features outlined in Table 2, section A, which are further corroborated by the endoscopic or histopathologic features listed in Table 2, sections B and C. Patients exhibiting these features 15 characteristic of left-sided or distal UC, have features of UC.

Pathology reports were obtained in 93% of the total study population (100%, 85% and 94% of pANCA-positive, cANCA-positive, and ANCA-negative CD subgroups, respectively). 20 Actual biopsies or surgical specimens were available for review by one of two pathologists with IBD expertise in 42% of the overall CD population (61%, 30%, and 35% of pANCA-positive, cANCA-negative, and ANCA-negative CD subgroups, respectively). Special attention was paid to the 25 character of inflammatory process (homogeneous/continuous versus focal inflammation within and between biopsy specimens), the depth of inflammation (superficial versus extension into submucosa or transmural inflammatory process), and the presence or absence of granulomas and crypt abscesses.

30

Distribution of clinical and epidemiological characteristics of Crohn's disease stratified according to ANCA status

A comparison of the clinical and epidemiological 35 characteristics of the pANCA-positive CD, cANCA-positive CD, and ANCA-negative CD subgroups is depicted in Table 3. No

significant relationship was detected between the presence of pANCA or cANCA and age, age of onset, disease duration, gender, or family history of IBD ($p_c > 0.05$). More patients were of Jewish descent in the cANCA-positive subgroup than in 5 the ANCA-negative group ($p_c = 0.025$). There was no significant difference in frequency of perforating or fistulizing disease in the pANCA-positive subgroup ($p_c > 0.10$). There was no significant difference in disease severity between the subgroups, as reflected by numbers of surgeries or years of 10 exposure to systemic steroid therapy ($p_c > 0.05$). The majority of CD patients in all three groups required immunomodulation.

Frequency of clinical symptoms of left-sided colonic inflammation in pANCA-positive Crohn's disease patients

Crohn's disease patients who were pANCA-positive more 15 often exhibited rectal bleeding and mucus discharge, than did the ANCA-negative CD subgroup ($p_c = 0.006$) or the cANCA-positive CD subgroup ($p_{Fisher's\ exact} = 0.09$) as shown in Figure 2. A trend towards increased urgency was also evident in the pANCA-positive subgroup. The higher prevalence of left-sided 20 symptoms in the pANCA-positive subgroup as compared with the ANCA-negative and cANCA-positive subgroups was reflected in the higher percent of pANCA-positive patients having been treated with topical agents ($p_c = 0.008$ and $c_p = 0.004$, respectively). A greater number of pANCA-positive CD patients 25 experienced diarrhea than those in the cANCA-positive CD ($p_{Fisher's\ exact} = 0.048$) and the ANCA-negative CD ($p > 0.112$) subgroups. Thus, symptoms of left-sided colonic inflammation such as rectal bleeding and mucous discharge, urgency, and treatment with local topical 5-ASA or steroid therapies were 30 more often present in pANCA-positive CD patients. Characteristic features of Crohn's disease exhibited by the pANCA+ CD patients are highlighted in Table 4.

Table 4

TI = Terminal ileum; S = stricture; SB = Small bowel; SBO = Small bowel obstruction; F = Fistula; A = Abscess; AU = Aphthous ulcers

Small bowel disease confirmed by radiographic, endoscopic, and/or histological evaluation

SUBSTITUTE SHEET (RULE 26)

pANCA-positive Crohn's disease patients do not have isolated small bowel inflammation

The anatomic location of documented Crohn's disease involvement for the pANCA-positive, cANCA-positive, and 5 ANCA-negative CD subgroups was categorized into "small bowel disease only", "ileocolonic disease", and "colonic involvement only." Ileocolonic involvement was observed in fifty percent of pANCA-positive CD patients, and the disease was limited to the colon in the other fifty percent. No patient in the 10 pANCA-positive CD subgroup had disease limited to the small bowel. Similarly, small bowel obstructive symptoms were exhibited less frequently in the pANCA-positive subgroup than in the other subgroups, although this difference did not reach statistical significance.

15 *Expression of serum pANCA is not related solely to the presence of colonic disease*

Colonic inflammation such as ileocolonic disease or colonic involvement only was present in 83% of the CD study population as shown in Figure 3. The majority of patients in 20 each subgroup had colonic involvement: 100% of the pANCA-positive CD subgroup, 70% of the cANCA-positive CD subgroup, and 81% in the ANCA-negative CD subgroup). There was no statistically significant difference between the proportion of pANCA-positive and ANCA-negative patients with 25 colonic disease ($p_{Fisher's\ exact}=0.07$). Of all CD patients with colonic involvement, 32% were pANCA-positive, while the majority of CD patients with colitis (68%) did not express serum pANCA. Thus, the expression of serum pANCA, is not related solely to the presence of colonic disease.

30 *Left-sided colitis is present in all pANCA-positive Crohn's disease patients*

Endoscopic or histopathologic inflammation of the rectum

or sigmoid colon was present in every pANCA-positive CD patient. The frequency of endoscopically or histopathologically documented left-sided colitis was significantly different when compared to either the 5 ANCA-negative ($p_c=0.002$) or cANCA+ ($p_{Fisher's\ exact}=0.001$) subgroup. There was no difference between the latter two subgroups ($p_c=1$).

pANCA-positive CD patients have features of ulcerative colitis

The absence of Crohn's involvement limited to the small 10 bowel and the clinical expression of symptoms of left-sided colonic inflammation, along with documented left-sided colitis are all features consistent with ulcerative colitis. In addition to their other features of CD, a subset of the CD study population was noted to have features of ulcerative 15 colitis. For these patients with Crohn's disease to be considered to have features of ulcerative colitis, they needed to, at minimum, have rectal bleeding, urgency and tenesmus, which are clinical features of left-sided colonic disease, in combination with a characteristic endoscopic feature 20 (inflammation that is more severe distally than proximally or continuous inflammation or a characteristic histopathologic feature (homogeneous, continuous, predominately superficial inflammation or lack of "focality" within biopsy specimens). Forty-six percent of all CD patients exhibiting features of 25 ulcerative colitis expressed serum pANCA. In contrast, none of the 30 CD patients lacking these features were pANCA-positive. This difference was highly significant. One hundred percent of pANCA-positive CD patients exhibited 30 features of ulcerative colitis. The number of patients having features of ulcerative colitis was 18/18 (100%) in the pANCA-positive CD subgroup; 9/20 (45%) in the cANCA-positive CD subgroup and 12/31 (39%) of patients in the ANCA-negative CD subgroup (see Table 5). Thus, the percent of 35 pANCA-positive CD patients with features of ulcerative colitis was significantly higher than the percent of patients meeting

the criteria in either the cANCA-positive or ANCA-negative subgroups.

Table 5			
Subtype of CD	ANCA-negative CD	cANCA-positive CD	pANCA-positive CD
Frequency of features of UC	39%	45%	100%

EXAMPLE II

**Frequency of the Arg²⁴¹ allele of ICAM-1 in subtypes of with
10 Crohn's disease stratified according to ANCA status**

This example demonstrates that the pANCA status of Crohn's disease patients correlates with the presence of the Arg²⁴¹ allele of Intracellular adhesion molecule-1 (ICAM-1).

**A. The ICAM-1 Arg²⁴¹ allele is associated with the
15 pANCA-positive subtype of CD**

Crohn's disease patients were subgrouped according to ANCA status and evaluated for the presence of the ICAM-1 Arg²⁴¹ allele. pANCA-positive patient status was determined as described in Example IA with both a fixed neutrophil ELISA using a 100-fold dilution of patient sera and immunofluorescence to determine the perinuclear or cytoplasmic staining pattern. CD patients that were determined to be pANCA-positive (n=14) had a significantly increased frequency of the Arg²⁴¹ allele (50%) as compared with pANCA-negative CD patients (15.7%; n=108) ($p=0.002$). The frequency of the Arg²⁴¹ allele in the cANCA-positive CD patient subgroup (15.4%; n=13) was similar to that of the ANCA-negative CD patient subgroup (15.8%; n=95) ($p=0.97$). The cANCA-positive and ANCA-negative CD subgroups had an Arg²⁴¹ allele frequency which was comparable to that of normal controls (13.9%; n=72) or ANCA-positive UC patients (cANCA-positive: 8.3%; n=12 and pANCA-positive: 11.1%; n=72). These results are summarized in Table 6.

Table 6			
	Subtype	Number of Patients	Frequency of Arg ²⁴¹ Allele
5	pANCA-positive CD	14	50%
	pANCA-negative CD	108	15.7%
	cANCA-positive CD	13	15.4%
	ANCA-negative CD	95	15.8%
	ANCA-positive UC	84	19.4%
	Control	72	13.9%

B. Detection of the Arg²⁴¹ allele

10 *Amplification of genomic nucleic acid including the ICAM-1 Arg²⁴¹ allele.*

The ICAM-1 Arg²⁴¹ allele was detected by a polymerase chain reaction (PCR) allele-specific oligonucleotide technique as described in Vora et al., *Genomics* 21:473-477 15 (1994), which is incorporated herein by reference. A pair of primers, 5'GATTGAAGAAGCCAGCAG3' (SEQ ID NO: 10) and 5'GTCGTTGCCATAGGTGAC3' (SEQ ID NO: 11), which flank codon 241, were used to amplify patient DNA as follows:

Genomic DNA was amplified using 20 μ l PCR reactions 20 under the following conditions: 10 mM Tris-HCl at pH 8.3, 50 mM KCl, 1.5mM MgCl₂, 200 μ M each dNTP, 10 μ M each primer, 50 ng of genomic DNA, and 0.5 units of AmpliTaq polymerase (Perkin-Elmer Cetus, Norwalk, CT). The DNA was amplified for 40 cycles: 94°C for 30 seconds 55°C for 30 seconds, and 25 72°C for 45 seconds for 40 cycles.

Allele-specific oligonucleotide PCR

Three microliters of the PCR product prepared as described above was applied to a Hybond N⁺ membrane (Amersham Lifesciences, Inc., Arlington Heights, IL) using a 30 Beckman Biomek Robot. The membranes were air dried and treated with denaturing solution (0.5 N NaOH) for 15

minutes, followed by renaturation in 2x SSC with 0.4 M tris at pH 7.5 for 10 minutes.

An allele-specific oligonucleotide probe was used to detect the Arg²⁴¹ allele (5'TCCCTGGACAGGCTGTTCC3') (SEQ ID NO: 9). Oligonucleotides were end-labeled with [γ -³²P]ATP using T4 polynucleotide kinase, and the membranes prehybridized in 10% polyethylene glycol, 7% SDS, 1% bovine serum albumin, 250 mM NaCl, and 250 mM sodium phosphate at 65°C. Hybridization was performed with 2-3 x 10⁶ cpm/10 ml of labeled allele-specific oligonucleotide probe (SEQ ID NO: 9) using 20-fold higher concentration of nonradioactive allele-specific oligonucleotide for the alternative allele (Gly²⁴¹). Hybridization was performed at 65°C for 30 minutes followed by continued hybridization at 37°C. The membranes were washed with 5x SSC at room temperature, followed by 2x SSC at 45°C for 30 minutes. Results were analyzed by autoradiography.

Although the invention has been described with reference to the examples above, it should be understood that various modifications can be made without departing from the spirit of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: CEDARS-SINAI MEDICAL CENTER

(ii) TITLE OF INVENTION: METHODS OF DIAGNOSING A CLINICAL SUBTYPE
OF CROHN'S DISEASE WITH FEATURES OF ULCERATIVE COLITIS

(iii) NUMBER OF SEQUENCES: 11

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pretty, Schroeder & Poplawski
(B) STREET: 444 S. Flower Street, Suite 2000
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: U.S.A.
(F) ZIP: 90071

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/689,873
(B) FILING DATE: 15-AUG-1996
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/630,672
(B) FILING DATE: 12-APR-1996

(A) APPLICATION NUMBER: US 08/689,873
(B) FILING DATE: 15-AUG-1996

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Fujita, Sharon M.
(B) REGISTRATION NUMBER: 38,459
(C) REFERENCE/DOCKET NUMBER: FP07 38539

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (213) 622-7700
(B) TELEFAX: (213) 489-4210

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1599 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1596

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GCT CCC AGC AGC CCC CGG CCC GCG CTG CCC GCA CTC CTG GTC CTG Met Ala Pro Ser Ser Pro Arg Pro Ala Leu Pro Ala Leu Leu Val Leu	48
1 5 10 15	
CTC GGG GCT CTG TTC CCA GGA CCT GGC AAT GCC GAG ACA TCT GTG TCC Leu Gly Ala Leu Phe Pro Gly Pro Gly Asn Ala Glu Thr Ser Val Ser	96
20 25 30	
CCC TCA AAA GTC ATC CTG CCC CGG GGA GGC TCC GTG CTG GTG ACA TGC Pro Ser Lys Val Ile Leu Pro Arg Gly Ser Val Leu Val Thr Cys	144
35 40 45	
AGC ACC TCC TGT GAC CAG CCC AAG TTG TTG GGC ATA GAG ACC CCG TTG Ser Thr Ser Cys Asp Gln Pro Lys Leu Leu Gly Ile Glu Thr Pro Leu	192
50 55 60	
CCT AAA AAG GAG TTG CTC CTG CCT GGG AAC AAC CGG AAG GTG TAT GAA Pro Lys Lys Glu Leu Leu Pro Gly Asn Asn Arg Lys Val Tyr Glu	240
65 70 75 80	
CTG AGC AAT GTG CAA GAA GAT AGC CAA CCA ATG TGC TAT TCA AAC TGC Leu Ser Asn Val Gln Glu Asp Ser Gln Pro Met Cys Tyr Ser Asn Cys	288
85 90 95	
CCT GAT GGG CAG TCA ACA GCT AAA ACC TTC CTC ACC GTG TAC TGG ACT Pro Asp Gly Gln Ser Thr Ala Lys Thr Phe Leu Thr Val Tyr Trp Thr	336
100 105 110	
CCA GAA CGG GTG GAA CTG GCA CCC CTC CCC TCT TGG CAG CCA GTG GGC Pro Glu Arg Val Glu Leu Ala Pro Leu Pro Ser Trp Gln Pro Val Gly	384
115 120 125	
AAG AAC CTT ACC CTA CGC TGC CAG GTG GAG GGT GGG GCA CCC CGG GCC Lys Asn Leu Thr Leu Arg Cys Gln Val Glu Gly Gly Ala Pro Arg Ala	432
130 135 140	
AAC CTC ACC GTG GTG CTG CTC CGT GGG GAG AAG GAG CTG AAA CGG GAG	480

Asn Leu Thr Val Val Leu Leu Arg Gly Glu Lys Glu Leu Lys Arg Glu 145 150 155 160 CCA GCT GTG GGG GAG CCC GCT GAG GTC ACG ACC ACG GTG CTG GTG AGG Pro Ala Val Gly Glu Pro Ala Glu Val Thr Thr Thr Val Leu Val Arg 165 170 175 AGA GAT CAC CAT GGA GCC AAT TTC TCG TGC CGC ACT GAA CTG GAC CTG Arg Asp His His Gly Ala Asn Phe Ser Cys Arg Thr Glu Leu Asp Leu 180 185 190 CGG CCC CAA GGG CTG GAG CTG TTT GAG AAC ACC TCG GCC CCC TAC CAG Arg Pro Gln Gly Leu Glu Leu Phe Glu Asn Thr Ser Ala Pro Tyr Gln 195 200 205 CTC CAG ACC TTT GTC CTG CCA GCG ACT CCC CCA CAA CTT GTC AGC CCC Leu Gln Thr Phe Val Leu Pro Ala Thr Pro Pro Gln Leu Val Ser Pro 210 215 220 CGG GTC CTA GAG GTG GAC ACG CAG GGG ACC GTG GTC TGT TCC CTG GAC Arg Val Leu Glu Val Asp Thr Gln Gly Thr Val Val Cys Ser Leu Asp 225 230 235 240 GGG CTG TTC CCA GTC TCG GAG GCC CAG GTC CAC CTG GCA CTG GGG GAC Gly Leu Phe Pro Val Ser Glu Ala Gln Val His Leu Ala Leu Gly Asp 245 250 255 CAG AGG TTG AAC CCC ACA GTC ACC TAT GGC AAC GAC TCC TTC TCG GCC Gln Arg Leu Asn Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser Ala 260 265 270 AAG GCC TCA GTC AGT GTG ACC GCA GAG GAC GAG GGC ACC CAG CGG CTG Lys Ala Ser Val Ser Val Thr Ala Glu Asp Glu Gly Thr Gln Arg Leu 275 280 285 ACG TGT GCA GTA ATA CTG GGG AAC CAG AGC CAG GAG ACA CTG CAG ACA Thr Cys Ala Val Ile Leu Gly Asn Gln Ser Gln Glu Thr Leu Gln Thr 290 295 300 GTG ACC ATC TAC AGC TTT CCG GCG CCC AAC GTG ATT CTG ACG AAG CCA Val Thr Ile Tyr Ser Phe Pro Ala Pro Asn Val Ile Leu Thr Lys Pro 305 310 315 320 GAG GTC TCA GAA GGG ACC GAG GTG ACA GTG AAG TGT GAG GCC CAC CCT Glu Val Ser Glu Gly Thr Glu Val Thr Val Lys Cys Glu Ala His Pro 325 330 335 AGA GCC AAG GTG ACG CTG AAT GGG GTT CCA GCC CAG CCA CTG GGC CCG Arg Ala Lys Val Thr Leu Asn Gly Val Pro Ala Gln Pro Leu Gly Pro 340 345 350 AGG GCC CAG CTC CTG CTG AAG GCC ACC CCA GAG GAC AAC GGG CGC AGC Arg Ala Gln Leu Leu Leu Lys Ala Thr Pro Glu Asp Asn Gly Arg Ser 355 360 365	528 576 624 672 720 768 816 864 912 960 1008 1056 1104
--	--

40

TTC TCC TGC TCT GCA ACC CTG GAG GTG GCC GGC CAG CTT ATA CAC AAG Phe Ser Cys Ser Ala Thr Leu Glu Val Ala Gly Gln Leu Ile His Lys 370 375 380	1152
AAC CAG ACC CGG GAG CTT CGT GTC CTG TAT GGC CCC CGA CTG GAC GAG Asn Gln Thr Arg Glu Leu Arg Val Leu Tyr Gly Pro Arg Leu Asp Glu 385 390 395 400	1200
AGG GAT TGT CCG GGA AAC TGG ACG TGG CCA GAA AAT TCC CAG CAG ACT Arg Asp Cys Pro Gly Asn Trp Thr Trp Pro Glu Asn Ser Gln Gln Thr 405 410 415	1248
CCA ATG TGC CAG GCT TGG GGG AAC CCA TTG CCC GAG CTC AAG TGT CTA Pro Met Cys Gln Ala Trp Gly Asn Pro Leu Pro Glu Leu Lys Cys Leu 420 425 430	1296
AAG GAT GGC ACT TTC CCA CTG CCC ATC GGG GAA TCA GTG ACT GTC ACT Lys Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu Ser Val Thr Val Thr 435 440 445	1344
CGA GAT CTT GAG GGC ACC TAC CTC TGT CGG GCC AGG AGC ACT CAA GGG Arg Asp Leu Glu Gly Thr Tyr Leu Cys Arg Ala Arg Ser Thr Gln Gly 450 455 460	1392
GAG GTC ACC CGC GAG GTG ACC GTG AAT GTG CTC TCC CCC CGG TAT GAG Glu Val Thr Arg Glu Val Thr Val Asn Val Leu Ser Pro Arg Tyr Glu 465 470 475 480	1440
ATT GTC ATC ATC ACT GTG GTA GCA GCC GCA GTC ATA ATG GGC ACT GCA Ile Val Ile Ile Thr Val Val Ala Ala Ala Val Ile Met Gly Thr Ala 485 490 495	1488
GGC CTC AGC ACG TAC CTC TAT AAC CGC CAG CGG AAG ATC AAG AAA TAC Gly Leu Ser Thr Tyr Leu Tyr Asn Arg Gln Arg Lys Ile Lys Lys Tyr 500 505 510	1536
AGA CTA CAA CAG GCC CAA AAA GGG ACC CCC ATG AAA CCG AAC ACA CAA Arg Leu Gln Gln Ala Gln Lys Gly Thr Pro Met Lys Pro Asn Thr Gln 515 520 525	1584
GCC ACG CCT CCC TGA Ala Thr Pro Pro 530	1599

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

41

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CTGCACG

7

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TGCACGG

7

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCACGGG

7

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

42

CACGGGC

7

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

ACGGGCT

7

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CGGGCTG

7

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: DNA (genomic)

- (iii) HYPOTHETICAL: NO

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGGCTGT

7

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TCCCTGGACA GGCTGTTCC

19

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GATTGAAGAA GCCAGCAG

18

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTCGTTGCCA TAGGTGAC

19

CLAIMS

1. A method of diagnosing a clinical subtype of Crohn's disease, comprising detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, wherein said Arg²⁴¹ allele indicates a clinical subtype of CD with features of ulcerative colitis.

2. The method of claim 1, wherein said detecting comprises:

- a) obtaining material from said patient;
- b) preparing a nucleic acid comprising nucleotide 721 of SEQ ID NO: 1 from said material;
- c) contacting said nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under conditions suitable for formation of a specific hybrid between said nucleic acid and said Arg²⁴¹ allele-specific oligonucleotide probe; and
- d) assaying for the presence of said specific hybrid, wherein the presence of said specific hybrid indicates said Arg²⁴¹ allele.

3. The method of claim 2, wherein preparing said nucleic acid further comprises enzymatic amplification of said nucleic acid.

4. The method of claim 3, wherein said Arg²⁴¹ allele-specific oligonucleotide probe is a nucleic acid molecule comprising a nucleic acid sequence selected from:

CTGCACG (SEQ ID NO: 2), or complementary sequence thereto;

TGCACGG (SEQ ID NO: 3), or complementary sequence thereto;

GCACGGG (SEQ ID NO: 4), or complementary sequence thereto;

CACGGGC (SEQ ID NO: 5), or complementary sequence thereto;

ACGGGCT (SEQ ID NO: 6), or complementary sequence

thereto;

CGGGCTG (SEQ ID NO: 7), or complementary sequence thereto; or

GGGCTGT (SEQ ID NO: 8), or complementary sequence thereto.

5. The method of claim 2, wherein said Arg²⁴¹ allele-specific oligonucleotide probe has the nucleic acid sequence shown as SEQ ID NO: 9, or complementary sequence thereto.

6. The method of claim 3, wherein said enzymatic amplification uses primer SEQ ID NO: 10.

7. The method of claim 3, wherein said enzymatic amplification uses primer SEQ ID NO: 11.

8. The method of claim 2, wherein preparing said nucleic acid further comprises endonuclease restriction of said nucleic acid.

9. A method of diagnosing a pANCA-positive subtype of CD, comprising detecting an Arg²⁴¹ allele at an ICAM-1 locus in a patient with CD, wherein said Arg²⁴¹ allele indicates a pANCA-positive subtype of Crohn's Disease.

10. The method of claim 9, wherein said detecting comprises:

- a) obtaining a sample from said patient;
- b) preparing a nucleic acid comprising nucleotide 721 of SEQ ID NO: 1 from said sample;
- c) contacting said nucleic acid with an Arg²⁴¹ allele-specific oligonucleotide probe under conditions suitable for formation of a specific hybrid between said nucleic acid and said Arg²⁴¹ allele-specific oligonucleotide probe; and
- d) assaying for the presence of said specific hybrid, wherein the presence of said specific hybrid indicates said Arg²⁴¹ allele.

11. The method of claim 10, wherein preparing said nucleic acid further comprises enzymatic amplification of said nucleic acid.

12. The method of claim 10, wherein said Arg²⁴¹ allele-specific oligonucleotide probe is a nucleic acid molecule comprising a nucleic acid sequence selected from:

CTGCACG (SEQ ID NO: 2), or complementary sequence thereto;

TGCACGG (SEQ ID NO: 3), or complementary sequence thereto;

GCACGGG (SEQ ID NO: 4), or complementary sequence thereto;

CACGGGC (SEQ ID NO: 5), or complementary sequence thereto;

ACGGGCT (SEQ ID NO: 6), or complementary sequence thereto;

CGGGCTG (SEQ ID NO: 7), or complementary sequence thereto; or

GGGCTGT (SEQ ID NO: 8), or complementary sequence thereto.


13. The method of claim 10, wherein said Arg²⁴¹ allele-specific oligonucleotide probe has the nucleic acid sequence shown as SEQ ID NO: 9, or complementary sequence thereto.

14. The method of claim 11, wherein said enzymatic amplification uses primer SEQ ID NO: 10.

15. The method of claim 11, where said enzymatic amplification uses primer SEQ ID NO: 11.


16. The method of claim 10, wherein preparing said nucleic acid further comprises endonuclease restriction of said nucleic acid.

1/6



2/6

FIG. 2



3/6




FIG. 3

4/6

FIG. 4-1

ICAM

ATG	GCT	CCC	AGC	AGC	CCC	CGG	CCC	GCG	CTG	CCC	GCA	CTC	CTG	GTC	CTG	48
Met	Ala	Pro	Ser	Ser	Pro	Arg	Pro	Ala	Leu	Pro	Ala	Leu	Leu	Val	Leu	
1		5							10					15		
CTC	GGG	GCT	CTG	TTC	CCA	GGA	CCT	GGC	AAT	GCC	GAG	ACA	TCT	GTG	TCC	96
Leu	Gly	Ala	Leu	Phe	Pro	Gly	Pro	Gly	Asn	Ala	Glu	Thr	Ser	Val	Ser	
20									25					30		
CCC	TCA	AAA	GTC	ATC	CTG	CCC	CGG	GGA	GGC	TCC	GTG	CTG	GTG	ACA	TGC	144
Pro	Ser	Lys	Val	Ile	Leu	Pro	Arg	Gly	Gly	Ser	Val	Leu	Val	Thr	Cys	
35									40					45		
AGC	ACC	TCC	TGT	GAC	CAG	CCC	AAG	TTG	TTG	GGC	ATA	GAG	ACC	CCG	TTG	192
Ser	Thr	Ser	Cys	Asp	Gln	Pro	Lys	Leu	Leu	Gly	Ile	Glu	Thr	Pro	Leu	
50								55						60		
CCT	AAA	AAG	GAG	TTG	CTC	CTG	CCT	GGG	AAC	AAC	CGG	AAG	GTG	TAT	GAA	240
Pro	Lys	Lys	Glu	Leu	Leu	Leu	Pro	Gly	Asn	Asn	Arg	Lys	Val	Tyr	Glu	
65								70						75		80
CTG	AGC	AAT	GTG	CAA	GAA	GAT	AGC	CAA	CCA	ATG	TGC	TAT	TCA	AAC	TGC	288
Leu	Ser	Asn	Val	Gln	Glu	Asp	Ser	Gln	Pro	Met	Cys	Tyr	Ser	Asn	Cys	
85									90						95	
CCT	GAT	GGG	CAG	TCA	ACA	GCT	AAA	ACC	TTC	CTC	ACC	GTG	TAC	TGG	ACT	336
Pro	Asp	Gly	Gln	Ser	Thr	Ala	Lys	Thr	Phe	Leu	Thr	Val	Tyr	Trp	Thr	
100								105						110		
CCA	GAA	CGG	GTG	GAA	CTG	GCA	CCC	CTC	CCC	TCT	TGG	CAG	CCA	GTG	GGC	384
Pro	Glu	Arg	Val	Glu	Leu	Ala	Pro	Leu	Pro	Ser	Trp	Gln	Pro	Val	Gly	
115								120						125		
AAG	AAC	CTT	ACC	CTA	CGC	TGC	CAG	GTG	GAG	GGT	GGG	GCA	CCC	CGG	GCC	432
Lys	Asn	Leu	Thr	Leu	Arg	Cys	Gln	Val	Glu	Gly	Gly	Ala	Pro	Arg	Ala	
130								135						140		
AAC	CTC	ACC	GTG	GTG	CTG	CTC	CGT	GGG	GAG	GAG	CTG	AAA	CGG	GAG	480	
Asn	Leu	Thr	Val	Val	Leu	Leu	Arg	Gly	Glu	Lys	Glu	Leu	Lys	Arg	Glu	
145								150						155		160
CCA	GCT	GTG	GGG	GAG	CCC	GCT	GAG	GTC	ACG	ACC	ACG	GTG	CTG	GTG	AGG	528
Pro	Ala	Val	Gly	Glu	Pro	Ala	Glu	Val	Thr	Thr	Thr	Val	Leu	Val	Arg	
165									170						175	

5/6

FIG. 4-2

AGA GAT CAC CAT GGA GCC AAT TTC TCG TGC CGC ACT GAA CTG GAC CTG	576
Arg Asp His His Gly Ala Asn Phe Ser Cys Arg Thr Glu Leu Asp Leu	
180 185 190	
CGG CCC CAA GGG CTG GAG CTG TTT GAG AAC ACC TCG GCC CCC TAC CAG	624
Arg Pro Gln Gly Leu Glu Leu Phe Glu Asn Thr Ser Ala Pro Tyr Gln	
195 200 205	
CTC CAG ACC TTT GTC CTG CCA GCG ACT CCC CCA CAA CTT GTC AGC CCC	672
Leu Gln Thr Phe Val Leu Pro Ala Thr Pro Pro Gln Leu Val Ser Pro	
210 215 220	
CGG GTC CTA GAG GTG GAC ACG CAG GGG ACC GTG GTC TGT TCC CTG GAC	720
Arg Val Leu Glu Val Asp Thr Gln Gly Thr Val Val Cys Ser Leu Asp	
225 230 235 240	
GGG CTG TTC CCA GTC TCG GAG GCC CAG GTC CAC CTG GCA CTG GGG GAC	768
Gly Leu Phe Pro Val Ser Glu Ala Gln Val His Leu Ala Leu Gly Asp	
245 250 255	
CAG AGG TTG AAC CCC ACA GTC ACC TAT GGC AAC GAC TCC TTC TCG GCC	816
Gln Arg Leu Asn Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser Ala	
260 265 270	
AAG GCC TCA GTC AGT GTG ACC GCA GAG GAC GAG GGC ACC CAG CGG CTG	864
Lys Ala Ser Val Ser Val Thr Ala Glu Asp Glu Gly Thr Gln Arg Leu	
275 280 285	
ACG TGT GCA GTA ATA CTG GGG AAC CAG AGC CAG GAG ACA CTG CAG ACA	912
Thr Cys Ala Val Ile Leu Gly Asn Gln Ser Gln Glu Thr Leu Gln Thr	
290 295 300	
GTG ACC ATC TAC AGC TTT CCG GCG CCC AAC GTG ATT CTG ACG AAG CCA	960
Val Thr Ile Tyr Ser Phe Pro Ala Pro Asn Val Ile Leu Thr Lys Pro	
305 310 315 320	
GAG GTC TCA GAA GGG ACC GAG GTG ACA GTG AAG TGT GAG GCC CAC CCT	1008
Glu Val Ser Glu Gly Thr Glu Val Thr Val Lys Cys Glu Ala His Pro	
325 330 335	
AGA GCC AAG GTG ACG CTG AAT GGG GTT CCA GCC CAG CCA CTG GGC CCG	1056
Arg Ala Lys Val Thr Leu Asn Gly Val Pro Ala Gln Pro Leu Gly Pro	
340 345 350	

6/6

FIG. 4-3

AGG GCC CAG CTC CTG CTG AAG GCC ACC CCA GAG GAC AAC GGG CGC AGC	1104
Arg Ala Gln Leu Leu Leu Lys Ala Thr Pro Glu Asp Asn Gly Arg Ser	
355	360
365	
TTC TCC TGC TCT GCA ACC CTG GAG GTG GCC GGC CAG CTT ATA CAC AAG	1152
Phe Ser Cys Ser Ala Thr Leu Glu Val Ala Gly Gln Leu Ile His Lys	
370	375
380	
AAC CAG ACC CGG GAG CTT CGT GTC CTG TAT GGC CCC CGA CTG GAC GAG	1200
Asn Gln Thr Arg Glu Leu Arg Val Leu Tyr Gly Pro Arg Leu Asp Glu	
385	390
395	400
AGG GAT TGT CCG GGA AAC TGG ACG TGG CCA GAA AAT TCC CAG CAG ACT	1248
Arg Asp Cys Pro Gly Asn Trp Thr Trp Pro Glu Asn Ser Gln Gln Thr	
405	410
415	
CCA ATG TGC CAG GCT TGG GGG AAC CCA TTG CCC GAG CTC AAG TGT CTA	1296
Pro Met Cys Gln Ala Trp Gly Asn Pro Leu Pro Glu Leu Lys Cys Leu	
420	425
430	
AAG GAT GGC ACT TTC CCA CTG CCC ATC GGG GAA TCA GTG ACT GTC ACT	1344
Lys Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu Ser Val Thr Val Thr	
435	440
445	
CGA GAT CTT GAG GGC ACC TAC CTC TGT CGG GCC AGG AGC ACT CAA GGG	1392
Arg Asp Leu Glu Gly Thr Tyr Leu Cys Arg Ala Arg Ser Thr Gln Gly	
450	455
460	
GAG GTC ACC CGC GAG GTG ACC GTG AAT GTG CTC TCC CCC CGG TAT GAG	1440
Glu Val Thr Arg Glu Val Thr Val Asn Val Leu Ser Pro Arg Tyr Glu	
465	470
475	480
ATT GTC ATC ATC ACT GTG GTA GCA GCC GCA GTC ATA ATG GGC ACT GCA	1488
Ile Val Ile Ile Thr Val Val Ala Ala Val Ile Met Gly Thr Ala	
485	490
495	
GGC CTC AGC ACG TAC CTC TAT AAC CGC CAG CGG AAG ATC AAG AAA TAC	1536
Gly Leu Ser Thr Tyr Leu Tyr Asn Arg Gln Arg Lys Ile Lys Lys Tyr	
500	505
510	
AGA CTA CAA CAG GCC CAA AAA GGG ACC CCC ATG AAA CCG AAC ACA CAA	1584
Arg Leu Gln Gln Ala Gln Lys Gly Thr Pro Met Lys Pro Asn Thr Gln	
515	520
525	
GCC ACG CCT CCC T GA	1599
Ala Thr Pro Pro	
530	

INTERNATIONAL SEARCH REPORT

International application No
PCT/US 97/06064

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>GASTROENTEROLOGY, vol. 110, June 1996, pages 1810-19, XP002040020 VASILIAUSKAS E ET AL: "Perinuclear antineutrophil cytoplasmic antibodies in patients with crohn's disease define a clinical subgroup" see the whole document</p> <p>---</p>	9
X	<p>GASTROENTEROLOGY, vol. 109, August 1995, pages 440-48, XP002040021 YANG H ET AL: "Intercellular Adhesion Molecule 1 gene associations with immunologic subsets of Inflammatory Bowel Disease" see the whole document</p> <p>---</p> <p style="text-align: right;">- / --</p>	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

8 September 1997

Date of mailing of the international search report

01.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

Internatio. Application No

PCT/US 97/06064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NATURE MEDICINE, vol. 1, no. 12, December 1995, pages 1241-3, XP002040022 TARGAN S ET AL: "Clarifying the causes of Crohn's" see page 1241, paragraph 2 ---	1-16
A	WO 95 21941 A (CEDARS SINAI MEDICAL CENTER) 17 August 1995 see the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/06064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9521941 A	17-08-95	AU 1742395 A CA 2183147 A	29-08-95 17-08-95
